Clinical Trial: Open-Label Safety Study of Solriamfetol in Subjects with Binge Eating Disorder

U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06878976) titled 'Open-Label Safety Study of Solriamfetol in Subjects with Binge Eating Disorder' on March 14.

Brief Summary: This is a Phase 3, multi-center, open-label study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.

Study Start Date: Feb. 20

Study Type: INTERVENTIONAL

Condition: Binge-Eating Disorder

Intervention: DRUG: Solriamfetol 75mg, 150 mg, or 300 mg

Taken once daily.

Recruitment Status: ENROLLING_BY_INVITATION

Sponsor: Axsome Therapeutics, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....